Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS).
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The aim of the study is determining the non-inferiority in the overall success rate and the
safety for a combination therapy with hydroxychloroquine plus low dose glucocorticoids
compared to that for high dose glucocorticoids at 3 and 9 months in patients with pulmonary
sarcoidosis.